Literature DB >> 3707277

[Homocystinuria. A type with vascular thrombosis and factor VII deficiency].

M F Ben Dridi, S Karoui, R Kastally, H A Gharbi, I Zaimi, R Ben Osman.   

Abstract

In homocystinuria, thrombosis is frequent (50% of the cases). The authors report a case of cystathionine-synthetase deficiency-induced homocystinuria associated with thrombosis of a common iliac vein. This patient presented with a blood coagulation disorder which was related to severe factor VII deficiency and which was corrected by treatment. Homocystinuria was pyridoxine independent as witnessed by the fact that Brand's reaction remained positive with vitamin B6 therapy and cystathionine. Cystathionine-synthetase activity measured in cultured fibroblasts increased only slightly with pyridoxine therapy. Treatment (Betaine, folic acid, vitamin B 12) induced the disappearance of plasma methionine. Clinically, the patient whose treatment came late in the course of her disease, was only slightly improved. Hypotheses about etiopathogenic mechanisms of this disease are discussed. Difficulties of treatment and diet are reviewed. The relative inefficacy of therapy, even in case with early treatment, makes antenatal diagnosis preferable to neonatal diagnosis.

Entities:  

Mesh:

Year:  1986        PMID: 3707277

Source DB:  PubMed          Journal:  Arch Fr Pediatr        ISSN: 0003-9764


  2 in total

1.  Homocysteine, factor VII and antithrombin III in subjects with different gene dosage for cystathionine beta-synthase.

Authors:  L Brattström; B Israelsson; L Tengborn; B Hultberg
Journal:  J Inherit Metab Dis       Date:  1989       Impact factor: 4.982

Review 2.  Associated prothrombotic conditions are probably responsible for the occurrence of thrombosis in almost all patients with congenital FVII deficiency. Critical review of the literature.

Authors:  A Girolami; F Tezza; R Scandellari; S Vettore; B Girolami
Journal:  J Thromb Thrombolysis       Date:  2010-08       Impact factor: 2.300

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.